Benzinga | Jan 8, 2021 10:59AM EST

Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $104

Raymond James maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Strong Buy and raises the price target from $78 to $104.